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Abstract: Turner syndrome (TS) is a common chromosomal disorder in women that is 
associated with the absence of one of the X chromosomes. Severe short stature and a lack of 
pubertal development characterize TS girls, causing psychosocial problems and reduced bone 
mass. The growth impairment in TS seems to be due to multiple factors including an abnormal 
growth hormone (GH) – insulin-like growth factor (IGF) – IGF binding protein axis and haplo-
insufﬁ  ciency of the short stature homeobox-containing gene. Growth hormone and sex steroid 
replacement therapy has enhanced growth, pubertal development, bone mass, and the quality of 
life of TS girls. Recombinant human GH (hGH) has improved the height potential of TS girls 
with varied results though, depending upon the dose of hGH and the age of induction of puberty. 
The best ﬁ  nal adult height and peak bone mass achievement results seem to be achieved when 
hGH therapy is started early and puberty is induced at the normal age of puberty in a regimen 
mimicking physiologic puberty. The initiation of estradiol therapy at an age-appropriate time 
may also help the TS patients avoid osteoporosis during adulthood. Recombinant hGH therapy 
in TS seems to be safe. Studies so far show no adverse effects on cardiac function, glucose 
metabolism or any association with neoplasms but research is still in progress to provide con-
clusive data on long-term safety.
Keywords: Turner syndrome, recombinant growth hormone, growth hormone deﬁ  ciency, 
SHOX gene, hormonal replacement therapy
Introduction
Turner syndrome (TS), the most common chromosomal disorder in women, results 
from the partial or complete absence (monosomy) of one of the X chromosomes. 
TS affects one in 2500 live female births and it may exist without (nonmosaic form) 
or with the presence (mosaic form) of a normal 46 XX or, rarely, a 46XY cell line. 
Abnormalities such as ring X and Xq isochromosomes are common in patients with 
classic TS features and many of these girls have phenotypes indistinguishable from 
those of girls with nonmosaic monosomy X. A variety of physical characteristics 
are present in TS. Short stature, ovarian dysgenesis and ovarian failure are the most 
prevalent abnormaliites. Streak gonads in TS are common and the girls with TS 
usually do not show any signs of breast development. Some girls with TS though 
have spontaneous puberty and manifest normal breast development. Other physical 
features of TS include facial dysmorphism with low-set ears, webbed neck, short neck, 
low-set hair-line, “shield chest” with an increased distance between the pre-pubertal 
breasts, cardiovascular defects, cubitus valgus, renal malformations, hearing loss and 
lymphedema (Nielsen and Wohlert 1991). Cognitive deﬁ  cits involved with nonverbal 
learning abilities and visuospatial skills and behavioral problems may also be present 
in TS (Rovet 2004).
Girls with TS many times manifest only very subtle physical features of TS of 
which short stature is the most prominent, even from a young age. Therefore, it is 
recommended that all girls with short stature and/or growth delay for which no medical Therapeutics and Clinical Risk Management 2008:4(6) 1178
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reason can be found to have a karyotype performed in order 
to investigate the possibility of the presence of TS (Nielsen 
and Wohlert 1991).
Growth
Girls with TS are born with intrauterine growth retardation 
and they exhibit growth failure during early childhood as early 
as 1 year of age. The growth delay worsens during puberty, 
because of the absence of the pubertal growth spurt, resulting 
in a strikingly short adult height approximately 20 cm. shorter 
than the mean adult height of normal women. Spontaneous 
puberty occurs in 10% to 20% of the girls with TS accompa-
nied by a small pubertal growth spurt but prepubertal growth 
and ﬁ  nal adult height in these cases are similar to those of TS 
girls without spontaneous puberty (Massa et al 1990).
In the past, it was thought that the etiology of the short 
stature in TS was due to a reduction in spontaneous growth 
hormone (GH) secretion. This was because 24-hour (24 h) 
GH studies in girls from the age of 9 to 20 years of age 
showed decreased mean 24 h GH concentrations (Lyon et al 
1985). After the observation though that estradiol ampliﬁ  es 
the neuroendocrine regulation of pulsatile GH release in 
normal pubertal girls (Ho et al 1987) it became evident that 
this decrease in the 24 h GH concentrations in the pubertal-
aged TS girls was due to their lack of estradiol. Estrogen 
replacement therapy in pubertal-aged TS girls normalizes the 
24 h integrated concentrations of GH, but the growth deﬁ  cit 
is still present in these girls (Zadik et al 1992). The growth 
impairment in the majority of TS individuals therefore, is 
not due to GH deﬁ  ciency although a small minority of TS 
girls may manifest classic GH deﬁ  ciency (abnormal GH 
concentrations after pharmacologic provocation) in addition 
to their abnormal karyotype. Pharmacologic provocation 
tests though, are not recommended unless the girl’s growth is 
clearly abnormal relative to that expected for TS determined 
by plotting lengths and heights on TS-speciﬁ  c growth curves 
(Rongen-Westerlaken et al 1997; Bondy 2007).
Despite the fact that GH deﬁ  ciency is not usually pres-
ent in TS, the GH – insulin-like growth factor (IGF) – IGF 
binding protein (IGFBP) axis is disturbed. Increased IGFBP-
3 proteolytic activity has been found in adult TS combined 
with low levels of circulating free IGF-I and increased levels 
of free IGF-II. Normal formation of the 150 kDa IGFBP-3 
ternary complex ( acid-labile subunit (ALS), IGF-I and 
IGFBP-3) is also disrupted in TS, together with decreased 
levels of intact IGFBP-1,- 2, and -4, and decreased bioactive 
IGF-I. These occur despite the presence of normal immuno-
reactive levels of total IGF-I, IGFBP-1, -2, -3 and -4 and ALS 
(Gravholt et al 2001). A sex hormone dependent IGFBP-3 
protease (serine protease) seems to lead to destabilization of 
the 150 kDa IGFBP-3 ternary complex in TS since hormone 
replacement therapy (HRT) with estrogen causes a marked 
reduction in IGFBP-3 proteolysis, suggesting modulation of 
the protease by sex hormones. Concurrently after HRT in TS, 
free IGF-II decreases while free IGF-I remains unchanged. 
The binary complex of IGF-I and IGFBP-1 increases in 
response to HRT, the proteolysis of IGFBP-3 normalizes, 
and accordingly leads to normalization of ternary complex 
formation (Gravholt et al 2006).
In 1997, haploinsufﬁ  ciency for the short stature homeobox-
containing gene (SHOX) was found to also contribute to the 
marked short stature found in TS (Rao et al 1997; Rao et al 
2001). The SHOX gene is located on the distal end of the X 
and Y chromosomes at Xp22.3 and Yp11.3 in the pseudoau-
tosomal region 1 (Marchini et al 2004; Munns et al 2004). It 
is essential for the regulation of chondrocyte proliferation and 
differentiation and it encodes a cell-type speciﬁ  c nuclear tran-
scriptional activator, primarily expressed in osteogenic cells 
(Rao et al 2001). SHOX acts as a repressor of growth plate 
fusion since it is speciﬁ  cally expressed in the growth plate in 
hypertrophic chondrocytes undergoing apoptosis (Marchini 
et al 2004; Munns et al 2004). The haploinsufﬁ  ciency of the 
SHOX gene may lead to premature growth plate fusion in the 
distal limbs in TS and it inﬂ  uences the short stature of XO 
females since two copies of this gene are required for normal 
height (Blaschke 2006). Individuals with SHOX deﬁ  ciency 
have variable degrees of growth impairment with or without 
a spectrum of skeletal anomalies (Blum et al 2007). A wide 
spectrum of abnormalities are associated with mutations 
or deletions of the SHOX gene ranging from short stature 
without dysmorphic abnormalities to a form of short stature 
characterized by disproportionate shortening of the forearms 
and lower legs, cubitus valgus, Madelung deformity, short 
fourth metacarpals and high-arched palate (Binder et al 2003). 
This skeletal anomaly is typically observed in patients with 
Leri-Weill syndrome and to a lesser degree in TS patients 
(Ogata 1993). It is noteworthy to add though, that the degree 
of short stature observed with simple haploinsufﬁ  ciency 
for the SHOX gene is not as severe as that observed in TS 
patients suggesting that haploinsufﬁ  ciency for additional 
genes located on the short arm of the X chromosome also 
contribute to the growth retardation seen in TS (Ogata et al 
1993; Zinn et al 2000; Rosenfeld 2007).
A recent study suggests that haploinsufﬁ  ciency of one or 
more genes in Xp22.3, the distal 8.3 megabases (Mb) of the 
X chromosome, is also responsible for the TS neurocognitive Therapeutics and Clinical Risk Management 2008:4(6) 1179
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phenotype which includes impaired visual-spatial abilities 
(Zinn et al 2007). This interval includes the 2.6 Mb Xp-Yp 
pseudoautosomal region (PAR1) but the study suggests that 
haploinsufﬁ  ciency of the SHOX gene does not cause TS 
neurocognitive phenotype.
Psychosocial status
Another view advocated by some researchers, is that the 
abnormal adult height in women with TS is a complex quali-
tative trait associated with additional genes that have not yet 
been identiﬁ  ed, and with aneuploidy or other forms of chro-
mosomal imbalance, as is present in chromosomal disorders 
such as Down’s syndrome (Haverkamp et al 1999).
Growth hormone therapy
Treatment of the short stature in TS has been historically 
based on psychosocial issues since it is not evident that there 
is an advantageous organic health beneﬁ  t by being taller 
with TS. Psychological studies of children with TS report 
that their short stature is most often associated with social 
competence. Shorter TS children are less competent socially 
and at a greater risk of social impairment with social isola-
tion and social ineptitude probably because of teasing and 
stigmatization by their peers (Rovet et al 1994).
Recombinant human GH (hGH) therapy is now routinely 
used to treat the growth impediment in girls with TS although 
many studies have shown varied results. Comparisons 
of the studies of the ﬁ  nal adult heights (FHA) of women 
with TS who were treated with hGH show height gains 
after treatment ranging from no signiﬁ  cant increase over 
the projected adult height (PAH) (Dacou-Voutetakis et al 
1998), signiﬁ  cant increases of 5 cm or more over the PAH 
(Taback et al 1996; Chu et al 1997; Carel et al 1998; Plotnick 
et al 1998; Rosenfeld et al 1998; Chernausek et al 2000; 
Ranke et al 2000; Reiter et al 2001; Quigley et al 2002; van 
Pareren et al 2003; Massa et al 2003; The Canadian Growth 
Hormone Advisory Committee 2005) to a mean height gain 
over the PAH of up to 16 cm using a higher dose of hGH 
(∼0.630 mg/kg/week) (Sas et al 1999a). The multicenter 
Canadian study (The Canadian Growth Hormone Advisory 
Committee 2005) employed a parallel, randomized control 
group that received no hGH and was followed to adult height 
showing a mean height gain due to GH of +7.2 cm. Also, the 
largest TS study to date which included 5500 TS patients, of 
which 1146 TS patients were treated to adult height using an 
hGH dose of 0.28 ± 0.08 mg/kg/week, reported a height SDS 
at the beginning of hGH treatment of –3.1 ± 0.9 and at adult 
height an SDS of –2.3 ± 1.1 (Ranke et al 2007).
To overcome the retarded growth in TS patients most 
studies have shown that high doses of hGH are needed induc-
ing sometimes “acromegalic” levels of IGF-I, suggesting the 
presence of GH or IGF-I resistance in the bones (Van Pareren 
et al 2003; Bannink et al 2006a). Which hGH dose to use is 
still an issue of debate but recombinant hGH therapy is usu-
ally started at the recommended dose of 0.375 mg/kg/week 
divided into daily injections which is the dose approved by 
the US Food and Drug Administration (Bondy 2007). Growth 
hormone treatment though in higher doses, as mentioned 
above, has been shown to enhance growth even more in girls 
with TS but this many times leads to abnormally high IGF-I 
levels. Since the long-term effects of exceedingly high IGF-I 
concentrations during the growth period are not known and 
there is a theoretical potential of increasing the risk of cancer 
this should be avoided (Sas et al 1999a; Bannink et al 2006a; 
Park et al 2004; Ranke et al 2007).
Factors that seem to be most predictive of taller 
adult stature in TS individuals are related to the following: 
(1) taller mean parental height, (2) taller height at initiation 
of therapy, (3) the response to hGH during the ﬁ  rst year of 
therapy, (4) mean dose of hGH/week, (5) taller height at the 
start of puberty and (6) age at the start of puberty (Wilson 
et al 1991; Welse et al 1993; Carel et al 1997; Hofman et al 
1997; Ranke et al 2000; Reiter et al 2001; Quigley et al 2002; 
Bondy 2007; Ranke et al 2007; Rosenfeld 2007).
Some compounding factors that may explain the vari-
ability in the response of TS girls to hGH therapy are 
genomic imprinting and certain polymorphisms present in 
these girls. A recent study revealed that 72% of nonmosaic 
45,X girls retain a maternal X whereas 86% of nonmosaic 
46,X,i(Xq) girls carry an intact paternal X chromosome. By 
using a linear model which included age and height at the 
initiation of hGH therapy, the girls with a maternal X were 
shown to have a greater mean height gain than those with a 
paternal X. Interestingly, girls with a maternal X also had 
a smaller chance of having sensorineural hearing loss than 
the girls with a paternal X (Hamelin et al 2006). Also a pro-
tein polymorphism of the GH receptor (GHR) based on the 
genomic deletion of exon 3 (d3-GHR) has been linked to a 
signiﬁ  cantly higher increment in height velocity of TS girls 
after the ﬁ  rst year of treatment with high-dose recombinant 
hGH (Binder et al 2006).
The optimal age of initiation of hGH therapy is still not 
well established. Most physicians start hGH when the height 
drops well below the 5th percentile on the growth chart, which 
is usually on the average around the age of 9 years (Saenger 
et al 1996). This results in a situation though where the TS Therapeutics and Clinical Risk Management 2008:4(6) 1180
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girls are usually far behind their peers in height for most 
of their childhood adding frequently to their psychosocial 
isolation (Siegel et al 1998). A recent study from the Toddler 
Turner Study has added greatly to our insight on the age of 
initiation of hGH therapy in TS (Davenport et al 2007). This 
trial initiated hGH therapy (0.35 mg/kg/week) in TS girls at 
2 years of age even before a signiﬁ  cant deceleration in the 
height velocity was apparent. During the 2 years of therapy 
in these very young TS girls it was shown that there was a 
signiﬁ  cant increase in height SDS (+1.1 SDS) in the treated 
girls compared with the non-treated age-matched controls. 
There were no signiﬁ  cant differences between the bone ages 
of the two groups and as expected the IGF-I and IGFBP-3 
levels increased in the hGH treated group within the normal 
concentrations for age. Following this study, it became 
apparent that the current thinking on the age of initiation of 
hGH therapy in girls with TS may need to be re-evaluated 
and new guidelines might need be instituted in order to pos-
sibly recommend hGH therapy at an earlier age in the TS 
girls instead of waiting for the deceleration in growth which 
is standard in TS. With earlier hGH therapy the girls with 
TS might have a chance to avoid the psychosocial isolation 
during childhood associated with the severe growth impair-
ment of TS. The age of the initiation of hGH therapy though 
is still a matter of debate and further studies are still needed 
to conclusively address this issue.
Oxandrolone therapy
In the initial randomized, multicenter trial which was ﬁ  rst 
reported in 1986, hGH was used alone or in combination 
with the androgen oxandrolone. After the completion of this 
trial, when the TS patients had attained their ﬁ  nal height, 
this combined therapy was shown to have a signiﬁ  cant 
impact on improving their growth and ﬁ  nal adult height 
(Rosenfeld et al 1986). The 17 TS girls who completed this 
initial trial with hGH alone (0.375 mg/kg/week) attained a 
ﬁ  nal height of 150.4 cm, which was 8.4 ± 4.5 cm above their 
projected adult heights. For the 43 TS girls treated with a 
combination of hGH (0.375 mg/kg/week) and oxandrolone 
(0.125 mg/kg/week), the mean adult height attained was 
152.1 cm, which was 10.3 ± 4.7 cm taller than their projected 
adult heights (Rosenfeld et al 1998). Oxandrolone is not 
used very often currently since hormone replacement with 
estradiol in combination with hGH has been shown to be 
a more effective therapeutical regimen (Reiter et al 2001). 
Therapy using oxandrolone at a usual dose of 0.05 mg/kg/day 
is used mostly in TS patients with extreme short stature 
who start hGH therapy after 9 years of age. Therapy may 
be continued until a satisfactory height has been attained or 
until growth potential is limited (bone age  14 years and 
growth velocity 2 cm/year) (Bondy 2006).
Estrogen therapy
Most studies have shown that the ﬁ  nal height of girls with TS 
seems to be maximized when estrogen therapy is combined 
with hGH. The optimal age of the initiation of estrogen 
therapy is at a normal pubertal age around 12 years of age 
(Reiter et al 2001; Quigley et al 2002). This is in contrast to 
the view that had prevailed till recently that delaying estro-
gen therapy till 15 years of age optimizes height potential 
(Rosenfeld et al 1986; Chernausek et al 2004). The reason 
for this dichotomy of views seems to be due to the fact 
that in some older studies younger TS girls were started on 
relatively large doses of conjugated estrogens in spite of 
the fact that it was clearly shown in 1983 that the effect of 
estradiol on growth has a biphasic effect, that is stimulatory 
at low doses and inhibitory at high doses (Ross et al 1983). 
The most current therapeutic trial of hGH and low-dose 
estrogen in TS girls, which had a duration of 20 years, 
decidedly showed that using very low doses of estradiol 
together with hGH at a normal pubertal age mimicking more 
closely the estrogen levels present in healthy girls at the time 
of puberty and increasing the estradiol dose as the TS girl 
progresses through puberty has a greatly enhancing effect 
on ﬁ  nal adult height (Ross et al 2007). While early studies 
indicated that delaying estrogen replacement could improve 
ﬁ  nal height outcomes in TS patients receiving hGH, this is 
not usually recommended, as delaying puberty in individuals 
who may already have a poor self-image may put them at a 
greater psycho-social disadvantage (Rosenfeld 2007). Start-
ing estradiol at approximately 12 years of age also allows 
the TS girls to attain a normal bone mass which can only be 
attained if estradiol is started at the normal age of puberty and 
continued throughout puberty and adulthood (Hogler et al 
2004). Health-related quality of life (HRQoL) evaluations 
of young women with TS who were treated long-term with 
hGH and sex steroid hormonal replacement therapy (HRT) 
showed that the women who had reached normal height and 
who had age-appropriate pubertal development had high 
scores on the HRQoL scales including “social functioning” 
and “role-emotional” scales (Bannink et al 2006b).
Many forms of estrogen are available for treating TS 
patients but oral estrogens have been most often used. Studies 
though show that transdermal and injectable depot forms 
of estradiol may be more physiologic alternatives to oral 
therapy (Ankarberg-Lindgren et al 2001; Piippo et al 2004; Therapeutics and Clinical Risk Management 2008:4(6) 1181
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Rosenﬁ  eld et al 2005; Soriano et al 2005; Bondy et al 2006). 
Replacement therapy is usually begun with one-tenth of the 
adult replacement dose. The initial dose (oral ethinlyestra-
diol: 2 μg/day) is then gradually increased over 2 to 3 years in 
order to fully mimic physiologic increases of estradiol during 
normal puberty so that normal breast and uterine develop-
ment may occur. The adult replacement doses which achieve 
estradiol levels in the normal range for young adult women 
are: oral ethinylestradiol: 20 μg/day, transdermal estradiol: 
0.1 mg/day or injectable estradiol cypionate: 2.5 mg/month 
(Bondy et al 2006). The addition of progestin is recom-
mended at least 2 years after starting estradiol or when 
breakthrough bleeding occurs. It is also imperative to teach 
the TS patient that estrogen therapy is usually required until 
the time of normal menopause (52–54 years of age) in order 
to maintain normal feminization and prevent osteoporosis in 
the future (Hogler et al 2004).
Bone mineral density
The effect of recombinant hGH therapy on bone mineral 
density (BMD) and body composition has also been studied 
in TS girls and it was found that GH treatment alone, without 
the combination with estradiol, had little effect on cortical or 
trabecular BMD although it did increase lean body mass and 
it reduced adiposity (Ari et al 2006). Also, whole body and 
lumbar spine BMD in adult TS patients who received only 
hGH therapy without hormone replacement therapy (HRT) 
with estradiol until the age of 17 showed decreased BMD 
which was not improved with HRT during adulthood since 
normal peak bone mass in these patients was never attained 
because of the delay in HRT (Suganuma et al 2003). This 
study emphasizes the importance of the initiation of estradiol 
therapy at a normal age of puberty in order to maximize peak 
bone mass at an appropriate age in order to avoid osteoporosis 
during adulthood.
Safety of therapy
The safety of hGH therapy in girls with TS has been an 
issue of much discussion. The effects of hGH on glucose 
metabolism has been addressed in many studies and although 
insulin levels increase signiﬁ  cantly during hGH therapy in 
TS, compared to baseline, no glucose intolerance was uncov-
ered and the insulin levels return to normal levels after the 
completion of the hGH therapy (Wilson et al 1991; Welse 
et al 1993; Sas et al 1999a; Van Teunenbrock et al 1999; 
Bannink et al 2006a). The impact of recombinant hGH 
therapy on the cardiovascular system has also been studied 
because many girls with TS have anatomic malformations 
affecting the heart, aorta and other major vessels, together 
with hypertension and abnormalities of heart rate, cardiac 
conduction and repolarization. Seven years of hGH treat-
ment in TS girls was shown to have no adverse effects on left 
ventricular heart dimensions or blood pressure (Wilson et al 
1991). Echocardiographical studies showed normal left ven-
tricular morphology and function in GH-treated TS girls and 
magnetic resonance angiography found no deleterious effects 
of hGH treatment on aortic diameter or compliance (Sas et al 
1999b; Radetti et al 2001; Bondy 2006; Vab deb et al 2006; 
Bondy 2007). Also no increased risk of neoplasia has been 
found in TS girls treated with hGH (Bondy 2007).
In conclusion, recombinant human GH therapy in com-
bination with estradiol starting at the normal age of puberty 
is the treatment of choice for the treatment of short stature 
in girls with TS. Growth hormone therapy seems to be safe, 
with no adverse effects so far, on glucose metabolism or car-
diac function or any association with neoplasms, but further 
studies are needed to give conclusive data on the issue of 
long-term safety. Nevertheless, most studies report that GH 
and estradiol therapy allows the girls with Turners Syndrome 
to attain normal adult height, pubertal development and bone 
mass and to maintain a good quality of life.
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